Alimentary pharmacology & therapeutics
Targets to improve quality of care for patients with hepatic encephalopathy: data from a multi-centre cohort.
Letter: vedolizumab drug levels in cord and maternal blood in women with inflammatory bowel disease-authors' reply.
Clinical and metabolic effects associated with weight changes and obeticholic acid in non-alcoholic steatohepatitis.
Editorial: vedolizumab in pregnancy - is gut selectivity as good for baby as it is for mum? Authors' reply.
Vedolizumab exposure in pregnancy: outcomes from clinical studies in inflammatory bowel disease.
Editorial: the management of IBD during pregnancy and lactation.
Commentary: treatment of hepatitis C-related cirrhosis in the era of direct-acting anti-virals - authors' reply.
Telaprevir or boceprevir triple therapy in patients with chronic hepatitis C and varying severity of cirrhosis.
Letter: Treatment for small intestinal bacterial overgrowth--where are we now? Authors' reply.
Commentary: Towards an effective and safe treatment of small intestine bacterial overgrowth - Authors' reply.
